Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016

Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016
Published Jun 30, 2016
70 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016, provides in depth analysis on Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted pipeline therapeutics.

The report provides comprehensive information on the Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62)
- The report reviews Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects
- The report assesses Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Caspase 9 (Apo

  
Source:
Document ID
GMDHC0198TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Overview71
Therapeutics Development84
  Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Stage of Development81
  Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Therapy Area91
  Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Indication102
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Companies143
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Products under Development by Universities/Institutes172
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Therapeutics Assessment197
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Companies Involved in Therapeutics Development265
  Bellicum Pharmaceuticals, Inc.261
  Conatus Pharmaceuticals Inc.271
  LG Life Science LTD.281
  Novelix Pharmaceuticals, Inc.291
  Pharmedartis GmbH301
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Drug Profiles3121
  BPX-501 Drug Profile314
  emricasan Drug Profile356
  flavokawain A Drug Profile411
  Granzyme B/VEGF Drug Profile421
  HaA-4 Drug Profile431
  nivocasan Drug Profile441
  NVX-207 Drug Profile451
  plinabulin Drug Profile464
  Recombinant Protein to Activate CASP3 and CASP9 for Oncology Drug Profile501
  Small Molecule to Activate Caspase 8, 9 for Oncology Drug Profile511
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Dormant Projects522
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Discontinued Products541
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) Featured News &Press Releases5514
  May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication551
  May 19, 2016: Bellicum Announces Data Presentation of BPX-501 at the European Hematology Association561
  May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO561
  May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial562
  Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data582
  Apr 05, 2016: Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Updates601
  Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting601
  Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering &Investment Forum in NYC611
  Feb 22, 2016: FDA Grants Orphan Drug Designation to Bellicum s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant621
  Feb 08, 2016: BeyondSpring Pharmaceuticals Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC621
  Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis631
  Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis641
  Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase651
  Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial661
  Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR s 2016 Tumor Microenvironment Special Conference672
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Caspase-9-Apoptotic-Protease-Mch-6-or-Apoptotic-Protease-Activating-Factor-3-or-ICE-Like-Apoptotic-Protease-6-or-EC-3-4-22-62-Pipeline-Review-H1-2016-2088-16093>
  
APA:
Global Markets Direct - Market Research. (2016). Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Caspase-9-Apoptotic-Protease-Mch-6-or-Apoptotic-Protease-Activating-Factor-3-or-ICE-Like-Apoptotic-Protease-6-or-EC-3-4-22-62-Pipeline-Review-H1-2016-2088-16093>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.